BCTX Stock Analysis: Buy, Sell, or Hold?
BCTX - Briacell Therapeutics Corp. Common Shares
$3.60
0.14 (4.05%)
▲
5d:
-2.44%
30d:
-11.98%
90d:
-3.23%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 21, 2026
0d
Get Alerted When BCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BCTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BCTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BCTX is currently trading at $3.60, which is considered oversold relative to its 30-day fair value range of $3.63 to $4.20.
Technical Outlook: Technically, BCTX is in a strong uptrend. Immediate support is located at $3.36, while resistance sits at $4.05. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: BCTX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $150.00 (+4066.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BCTX is in a strong uptrend. Immediate support is located at $3.36, while resistance sits at $4.05. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: BCTX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $150.00 (+4066.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.63 -
$4.20
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 4066.7% below Wall St target ($150.00)
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$3.63 -
$4.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.36
Resistance Level
$4.05
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.06
Wall Street Target
$150.00
(+4066.7%)
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 69 BUY |
